Zhou X, Wang J, Zhang J, Copley-Merriman K, Torigoe Y, Reyes C. Symptoms and toxicity of rituximab maintenance (R-M) versus observation (OBS) following rituximab plus chemotherapy in patients with follicular lymphoma. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3661. doi: 10.1182/blood.V118.21.3661.3661
Kiladjian J, Al-Ali H, Gisslinger H, Knoops L, Waltzman RJ, Mendelson E, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):795. doi: 10.1182/blood.V118.21.795.795
Walter JW, Spinner DS, Birt J, Bowman L, Mauskopf JA, Drummond M, Copley-Merriman K. Clinical and economic evidence bases for health technology assessment: a comparison of three jurisdictions. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain.
Sood V, Braun L, Hogue S, Davis K, Copley-Merriman C, Lieberman B. Chronic kidney disease burdens patients, health care systems, and employers. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A331.
Nelson LM, Nixon A, Copley-Merriman K. Documenting PRO evidence for regulatory submissions to support labeling claims. Poster presented at the International Society for Quality of Life Research Workshop #2; October 2011.
Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M. Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care. 2011 Jul 1;27(3):261-70.
Mordin M, Clark M, DeMuro C, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Pro label claims: an analysis based on a review of pros among new molecular entities and biologic license applications 2006-2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
DeMuro C, Mordin M, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
Coleman C, Chang S, Copley-Merriman K, Masaquel CJ, Hubble J. Health-related quality-of-life improvements with dysport in cervical dystonia. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 26, 2011. [abstract] Value Health. 2011 May; 14(3):A210.
Colosia AD, Peltz G, Pohl G, Liu E, Copley-Merriman K, Khan S, Kaye JA. A review and characterization of the various perceptions of quality cancer care. Cancer. 2011 Mar 1;117(5):884-96.